Biogen Defends Alzheimer’s Drug Trials in Clash With Investors
https://news.bloomberglaw.com/healt...lzheimers-drug-trials-in-clash-with-investors
- Company accused of manipulating efficacy data
- FDA’s approval of drug was controversial
The success of Biogen Inc.'s attempt to block a lawsuit from investors over the way it presented data about the efficacy of its costly Alzheimer’s drug, Aduhelm, will come down to the way the First Circuit interprets one sentence said by an executive on an earnings call.
“You really need to get to the higher dose” of Aduhelm, Biogen’s former Chief Medical Officer Alfred Sandrock told investors in July 2020, explaining why one of its clinical trials failed while the other succeeded. “And I think our data are all consistent with that,” Sandrock said.
https://news.bloomberglaw.com/healt...lzheimers-drug-trials-in-clash-with-investors
- Company accused of manipulating efficacy data
- FDA’s approval of drug was controversial
The success of Biogen Inc.'s attempt to block a lawsuit from investors over the way it presented data about the efficacy of its costly Alzheimer’s drug, Aduhelm, will come down to the way the First Circuit interprets one sentence said by an executive on an earnings call.
“You really need to get to the higher dose” of Aduhelm, Biogen’s former Chief Medical Officer Alfred Sandrock told investors in July 2020, explaining why one of its clinical trials failed while the other succeeded. “And I think our data are all consistent with that,” Sandrock said.